2010 GI Intro

Article

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting. See the links below for American Society of Clinical Oncology GI Cancer session cover from GI cancer specialists Richard M. Goldberg, MD, Lineberger Comprehensive Cancer Center and Peter C. Enzinger, MD, Dana-Farber Cancer Institute

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting. See the links below for American Society of Clinical Oncology GI Cancer session cover from GI cancer specialists Richard M. Goldberg, MD, Lineberger Comprehensive Cancer Center and Peter C. Enzinger, MD, Dana-Farber Cancer Institute

Recent Videos
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
2 experts are featured in this series.
1 expert in this video
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Related Content
TTFields/Chemotherapy Improves Survival in Advanced Pancreatic Cancer

TTFields/Chemotherapy Improves Survival in Advanced Pancreatic Cancer

Tim Cortese
Published: December 3rd 2024 | Updated: December 3rd 2024
Article

Tumor treating fields with chemotherapy improved overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

ASH 2024 Preview for Integrative Care: The Show and After Show

ASH 2024 Preview for Integrative Care: The Show and After Show

Kristie L. Kahl
December 3rd 2024
Article

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

EC Approves Ribociclib/Aromatase Inhibitor For HR+/HER2– Early Breast Cancer

EC Approves Ribociclib/Aromatase Inhibitor For HR+/HER2– Early Breast Cancer

Tim Cortese
December 2nd 2024
Article

The European Commission has approved ribociclib plus an aromatase inhibitor for patients with early breast cancer.

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Tim Cortese
December 1st 2024
Article

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.